Salarius Announces Allowance of New European Patent Covering Seclidemstat
04 mars 2020 08h00 HE
|
Salarius Pharmaceuticals
European Patent Office Satisfied Patent Application Meets All Requirements Salarius’ Global Intellectual Property Estate Includes 22 Issued Patents in the U.S., Europe and 12 Other Jurisdictions ...
Salarius Pharmaceuticals to Attend the Oppenheimer Healthcare Conference
02 mars 2020 08h00 HE
|
Salarius Pharmaceuticals
HOUSTON, March 02, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, announced today...
Salarius Announces Closing of $11.0 Million Underwritten Public Offering and Full Exercise of Over-Allotment Option
11 févr. 2020 16h05 HE
|
Salarius Pharmaceuticals
HOUSTON, Feb. 11, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting cancers caused by dysregulated gene expression, today announced...
Salarius Pharmaceuticals to Present at the Noble Capital Markets’ 16th Annual Small & Microcap Investor Conference
10 févr. 2020 08h00 HE
|
Salarius Pharmaceuticals
HOUSTON, Feb. 10, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced...
Salarius Announces Pricing of $9.6 Million Underwritten Public Offering
07 févr. 2020 08h30 HE
|
Salarius Pharmaceuticals
HOUSTON, Feb. 07, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancer, today announced the pricing of...
Salarius Pharmaceuticals to Present at the BIO CEO & Investor Conference
05 févr. 2020 08h00 HE
|
Salarius Pharmaceuticals
HOUSTON, Feb. 05, 2020 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced...
Salarius Announces Publication of Scientific Paper Highlighting Potential of Combining Seclidemstat with Checkpoint Inhibitors
04 févr. 2020 08h00 HE
|
Salarius Pharmaceuticals
Seclidemstat Modulates Tumor Microenvironment to Help Genetically Mutated Cancer Types Overcome Resistance to Checkpoint Inhibitors in Preclinical Study Data Supports Continued Study of Seclidemstat...
Salarius Pharmaceuticals to Present at Biotech Showcase 2020
19 déc. 2019 08h00 HE
|
Salarius Pharmaceuticals
HOUSTON, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, referred...
Salarius Pharmaceuticals Hosting Key Opinion Leader Call on Epigenetics, The Regulatory System That Affects Gene Expression
17 déc. 2019 08h00 HE
|
Salarius Pharmaceuticals
HOUSTON, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, today announced that it will...
Salarius Pharmaceuticals Receives FDA Fast Track Designation for Lead Drug Candidate, Seclidemstat, in Relapsed or Refractory Ewing Sarcoma
16 déc. 2019 08h00 HE
|
Salarius Pharmaceuticals
HOUSTON, Dec. 16, 2019 (GLOBE NEWSWIRE) -- Salarius Pharmaceuticals, Inc. (Nasdaq: SLRX), a clinical-stage biotechnology company targeting cancers caused by mis-regulated gene expression, announced...